A cohort of biomarkers have been reported to predict prognosis in clinical practice, which includes PD-L1, TMB, tumor infiltrating lymphocytes (TILS), T-cell receptor clonality, and gene signatures [13–16]. This evidence concerns the gene CD274 and neoplasm.